Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Completed 3Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 6NETWORK 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Small Cell Lung Carcinoma 1Sarcoma 1Ovarian Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × beta-D-glucosylisophosphoramide mustard × Clear all
NCT01954992 2024-12-31

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT00441467 2015-03-25

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Eleison Pharmaceuticals LLC.

Phase 2 Completed
22 enrolled 9 charts
Sarcoma

Sarcoma

NCT00442598 2015-03-10

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Eleison Pharmaceuticals LLC.

Phase 2 Terminated
17 enrolled 9 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00099294 2009-04-30

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Threshold Pharmaceuticals

Phase 3 Completed
300 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT00102752 2009-04-30

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

Threshold Pharmaceuticals

Phase 1/2 Completed
47 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT00435578 2009-04-30

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

Threshold Pharmaceuticals

Phase 2 Terminated
50 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡